2015 target of 45 introductions achieved more than one year ahead of schedule
In April 2015, Bangladesh introduced the pneumococcal vaccine alongside inactivated polio vaccine. As a result, one of the world’s largest birth cohorts – three million children – is now being targeted with two life-saving vaccines. This required training health workers and strengthening the national cold chain. Photo: Gavi/GMB Akash.
Roll-out across three continents
The roll-out of pneumococcal vaccines in developing countries is underway across three continents: over 50 Gavi-supported countries have started rolling out pneumococcal vaccines since 2010.
Pneumococcal vaccines are highly complex and sophisticated vaccines that in the past might have taken 15 years or more to reach lower-income countries. Thanks to the work of Gavi, its donors and Vaccine Alliance partners, the world's poorest children are now receiving the newest pneumococcal vaccines simultaneously with children in high-income countries.
Pneumococcal vaccine roll-outs
Gavi aimed to roll out the pneumococcal vaccine in 45 countries by 2015. This target was reached already in November 2014, 13 months ahead of schedule, when Georgia added the vaccine to its routine immunisation schedule. More than 50 countries have now rolled out the vaccine.
More than 50 countries approved
Strong demand means that pneumococcal vaccines are now being administered in more than half of all Gavi–supported countries. More than 50 countries have been approved for Gavi support to introduce the vaccine into their national immunisation programmes.
By rapidly increasing both the number of countries and the number of children receiving the vaccines, Gavi and its partners have immunised an estimated 47 million children with pneumococcal vaccines.
While coverage levels increased to 28% in 2014, they are still falling behind annual targets for the 2011–2015 period. This is largely the result of supply issues in the early years of the programme and delayed introductions in countries with large populations. Vaccine Alliance partners are working to ensure that supply remains stable, that adequate support is provided for remaining introductions and that coverage is sustained over the long term.
Advance Market Commitment
The implementation of this AMC is on track ... reducing morbidity and mortality from pneumococcal diseases in developing countries
Source: AMC process and design evaluation
The introduction of these vaccines is largely thanks to the generosity of Italy, the United Kingdom, Canada, the Russian Federation, Norway, and the Bill & Melinda Gates Foundation who together contributed US$ 1.5 billion through an innovative financing mechanism, called the Advance Market Commitment (AMC) for pneumococcal vaccines.
The aim of the AMC is to stimulate the development and manufacture of new vaccines for developing countries.
Two manufacturers have thus far committed to supply 600 million doses over the next 10 years. It is expected that additional manufacturers will have new pneumococcal vaccines ready to participate in the AMC in future years.
Map of countries approved for Gavi's pneumococcal vaccine support